Floatz logo

bmd006

Metastatic Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

275 Active assets in the Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

bmd006 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
Advanced Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →
Lung MetastasisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →